This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Wendell P. Weeks net worth and biography

Wendell Weeks Biography and Net Worth

Director of Merck & Co., Inc.

Mr. Wendell P. Weeks has been the Chief Executive Officer and President of Corning Incorporated since April 26, 2005 and December 2010 respectively and has been its Chairman since April 26, 2007. Mr. Weeks has been an Executive Director of Corning Incorporated since December 2000. Mr. Weeks has 32 years of Corning experience including financial management, business development, commercial leadership and general management. His experiences in many of Corning's businesses and technologies and 11 years as Chief Executive Officer, have given him a unique understanding of Corning's diverse business operations and innovations. He served as the Chairman and Chief Executive Officer of Dow Corning Corporation since April 26, 2007. He served as the President of Corning Incorporated from 2002 to April 2007 and served as its Chief Operating Officer from 2002 to April 28, 2005. Since 2001, he served as the President of Corning's Optical Communications Group, where he helped restructure the business during one of the toughest economic downturns in the telecommunications industry and also served as its Chief Operating Officer since 2002. Mr. Weeks joined Corning in 1983 and served as its Vice President and Deputy General Manager of the Opto-Electronics Components Business since 1995, Vice President and General Manager of Telecommunications Products since 1996, Senior Vice President since 1997, Senior Vice President of Opto-Electronics since 1998, Executive Vice President of Optical Communications since 1999 and President of Corning Optical Technologies since 2001. He served as a Staff Accountant of Price Waterhouse. He has been an Independent Director of Merck & Co., Inc. since February 24, 2004. He has been a Director of Amazon.com, Inc. since February 10, 2016. He serves as a Director of the Corning Museum of Glass and the Corning Incorporated Foundation. He served as a Director of Dow Corning Corporation since 2000. Mr. Weeks holds an MBA from Harvard Business School in 1987 as a Baker Scholar and a Bachelor's degree in Accounting and Finance from Lehigh University in 1981.

What is Wendell P. Weeks' net worth?: The estimated net worth of Wendell P. Weeks is at least $107.64 million as of July 26th, 2023. Mr. Weeks owns 847,474 shares of Merck & Co., Inc. stock worth more than $107,637,673 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Weeks may own. Learn More about Wendell P. Weeks' net worth.
How do I contact Wendell P. Weeks?: The corporate mailing address for Mr. Weeks and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Wendell P. Weeks' contact information.
Has Wendell P. Weeks been buying or selling shares of Merck & Co., Inc.?: Wendell P. Weeks has not been actively trading shares of Merck & Co., Inc. during the last ninety days. Most recently, Wendell P. Weeks sold 5,000 shares of the business's stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $76.02, for a transaction totalling $380,100.00. Following the completion of the sale, the director now directly owns 5,100 shares of the company's stock, valued at $387,702. Learn More on Wendell P. Weeks' trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 3 shares worth more than $341.04. During the last year, insiders at the sold shares 11 times. They sold a total of 460,551 shares worth more than $53,354,373.87. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Wendell P. Weeks Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/7/2020	Sell	5,000	$76.02	$380,100.00	5,100
2/13/2019	Sell	5,000	$78.71	$393,550.00	5,100
2/9/2018	Sell	5,000	$53.57	$267,850.00	5,100
2/6/2017	Sell	5,000	$64.51	$322,550.00	5,100
11/4/2015	Sell	5,000	$55.53	$277,650.00	100
11/24/2014	Sell	5,000	$59.13	$295,650.00

Wendell P. Weeks Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $127.01

$125.35

$127.59

50 Day Range

MA: $126.26

$120.54

$131.95

2 Week Range

Now: $127.01

$99.14

$133.10

Volume

7,105,057 shs

Average Volume

6,831,161 shs

Market Capitalization

$321.72 billion

P/E Ratio

907.21

Dividend Yield

2.43%

Beta

0.38